Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma

Expert Rev Anticancer Ther. 2023 Feb;23(2):117-120. doi: 10.1080/14737140.2023.2152795. Epub 2022 Nov 30.

Authors

Aaron C Tan^{1

2}, Keigo Kobayashi¹, Stephanie P L Saw^{1

2}, Daniel S W Tan^{1

2}, Darren Wan-Teck Lim^{1

2}

Affiliations

¹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
² Duke-NUS Medical School, National University of Singapore, Singapore.

PMID: 36426628
DOI: 10.1080/14737140.2023.2152795

No abstract available

Keywords: EGFR mutation; immunotherapy; lung cancer; non-small cell lung cancer.

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors / genetics
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

ErbB Receptors
Protein Kinase Inhibitors
EGFR protein, human